Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival Meeting Abstract
| Authors: | Tempero, M.; O'Reilly, E.; Van Cutsem, E.; Berlin, J.; Philip, P.; Goldstein, D.; Tabernero, J.; Borad, M.; Bachet, J.; Parner, V.; Tebbutt, N.; Chua, Y.; Corrie, P.; Harris, M.; Taieb, J.; Burge, M.; Kunzmann, V.; Zhang, G.; McGovern, D.; Marks, H.; Biankin, A.; Reni, M. |
| Abstract Title: | Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival |
| Meeting Title: | ESMO 23rd World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2021 Jun 30-Jul 3 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-07-01 |
| Start Page: | S226 |
| Language: | English |
| ACCESSION: | WOS:000670004200347 |
| DOI: | 10.1016/j.annonc.2021.06.009 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA-1 -- Source: Wos |
